Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | Latest advances in BP-MPNs

Guillermo Ortí • 21 Mar 2022
EBMT 2022
Myeloproliferative Neoplasms Ruxolitinib Venetoclax

Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, gives an overview of the latest developments in blast phase myeloproliferative neoplasms (BP-MPNs). Dr Ortí mentions the recent introduction of venetoclax, as well as new combinations including ruxolitinib and hypomethylating agents (HMAs), and new data on allogeneic hematopoietic stem cell transplantation (alloHSCT) that will be presented at EBMT. These advances are expected to reduce the relapse risk and the transformation risk in this patient population. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Guillermo Ortí

1:39
Emerging therapeutic approaches for TKI-resistant CML
Guillermo Ortí • 21 Mar 2022
1:23
Current status of alloHSCT in BP-MPNs
Guillermo Ortí • 21 Mar 2022
1:23
PTCy in unrelated and haploidentical donor alloHSCT in CML
Guillermo Ortí • 21 Mar 2022
1:47
State of the art in CML
Guillermo Ortí • 21 Mar 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals